These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9892183

  • 1. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity.
    Labourier E, Riou JF, Prudhomme M, Carrasco C, Bailly C, Tazi J.
    Cancer Res; 1999 Jan 01; 59(1):52-5. PubMed ID: 9892183
    [Abstract] [Full Text] [Related]

  • 2. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
    Pilch B, Allemand E, Facompré M, Bailly C, Riou JF, Soret J, Tazi J.
    Cancer Res; 2001 Sep 15; 61(18):6876-84. PubMed ID: 11559564
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C, Qu X, Chaires JB, Colson P, Houssier C, Ohkubo M, Nishimura S, Yoshinari T.
    J Med Chem; 1999 Jul 29; 42(15):2927-35. PubMed ID: 10425102
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X, Chaires JB, Ohkubo M, Yoshinari T, Nishimura S, Bailly C.
    Anticancer Drug Des; 1999 Oct 29; 14(5):433-42. PubMed ID: 10766298
    [Abstract] [Full Text] [Related]

  • 9. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110.
    Yoshinari T, Yamada A, Uemura D, Nomura K, Arakawa H, Kojiri K, Yoshida E, Suda H, Okura A.
    Cancer Res; 1993 Feb 01; 53(3):490-4. PubMed ID: 8381047
    [Abstract] [Full Text] [Related]

  • 10. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C, Carrasco C, Hamy F, Vezin H, Prudhomme M, Saleem A, Rubin E.
    Biochemistry; 1999 Jul 06; 38(27):8605-11. PubMed ID: 10393535
    [Abstract] [Full Text] [Related]

  • 11. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
    Bailly C, Dassonneville L, Colson P, Houssier C, Fukasawa K, Nishimura S, Yoshinari T.
    Cancer Res; 1999 Jun 15; 59(12):2853-60. PubMed ID: 10383146
    [Abstract] [Full Text] [Related]

  • 12. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B, Riou JF, Lavelle F, Pommier Y.
    Mol Pharmacol; 1993 Oct 15; 44(4):767-74. PubMed ID: 8232227
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
    Das BB, Sen N, Roy A, Dasgupta SB, Ganguly A, Mohanta BC, Dinda B, Majumder HK.
    Nucleic Acids Res; 2006 Oct 15; 34(4):1121-32. PubMed ID: 16488884
    [Abstract] [Full Text] [Related]

  • 18. Indolocarbazole glycosides in inactive conformations.
    Facompré M, Carrasco C, Vezin H, Chisholm JD, Yoburn JC, Van Vranken DL, Bailly C.
    Chembiochem; 2003 May 09; 4(5):386-95. PubMed ID: 12740810
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.
    Castelli S, Vassallo O, Katkar P, Che CM, Sun RW, Desideri A.
    Arch Biochem Biophys; 2011 Dec 15; 516(2):108-12. PubMed ID: 22033340
    [Abstract] [Full Text] [Related]

  • 20. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T, Ohkubo M, Fukasawa K, Egashira S, Hara Y, Matsumoto M, Nakai K, Arakawa H, Morishima H, Nishimura S.
    Cancer Res; 1999 Sep 01; 59(17):4271-5. PubMed ID: 10485471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.